Calzada Limited (CALZF) 0.1000 $CALZF
Global Cachexia Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pggqhv/cachexia) has announced the addition of the "Cachexia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cachexia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cachexia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cachexia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cachexia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - GlaxoSmithKline plc - Plexxikon Inc. - BioLineRx, Ltd. - Novartis AG - Aphios Corporation - Calzada Limited - Palatin Technologies, Inc. - Cytokinetics, Incorporated - Fate Therapeutics, Inc. - AVEO Pharmaceuticals, Inc. - Fountain Biopharma Inc. - Rhythm Pharmaceuticals - MI.TO. Technology S.r.L. For more information visit http://www.researchandmarkets.com/research/pggqhv/cachexia
Cartilage Degeneration - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 17, 3:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/hzb6kb/cartilage) has announced the addition of the "Cartilage Degeneration - Pipeline Review, H2 2013" report to their offering. 'Cartilage Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cartilage Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cartilage Degeneration. Scope - A snapshot of the global therapeutic scenario for Cartilage Degeneration. - A review of the Cartilage Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cartilage Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cartilage Degeneration Overview Therapeutics Development Clinical Stage Products Early Stage Products Cartilage Degeneration - Products under Development by Companies Cartilage Degeneration - Companies Involved in Therapeutics Development Cartilage Degeneration - Therapeutics Assessment Drug Profiles sprifermin - Drug Profile Chondrogen - Drug Profile MSB-CAR-001 - Drug Profile AOD-9604 - Drug Profile THR-166 - Drug Profile ST-03 - Drug Profile Cartilage Degeneration - Recent Pipeline Updates Appendix List of Tables List of Figures Companies Mentioned Sanofi Merck KGaA Mesoblast Limited Calzada Limited Thrasos, Inc. For more information visit http://www.researchandmarkets.com/research/hzb6kb/cartilage About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Bone Degeneration Market Report 2013
M2 - Mon Dec 09, 6:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/94cktb/bone_degeneration) has announced the addition of the "Global Bone Degeneration Market Report 2013" report to their offering. This report provides information on the therapeutic development for Bone Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Degeneration. The analysis is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Bone Degeneration. - A review of the Bone Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bone Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bone Degeneration. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bone Degeneration pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: Table of Contents List of Tables List of Figures Introduction REPORT COVERAGE Bone Degeneration Overview Therapeutics Development Companies Involved in Bone Degeneration Therapeutics Development Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Amgen Inc. - Cell Therapeutics, Inc. - Calzada Limited - Alethia Biotherapeutics Inc. - Fate Therapeutics, Inc. - Se-cure Pharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/94...generation
Osteoporosis - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Osteoporosis
M2 - Tue Sep 03, 9:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9tgmch/osteoporosis) has announced the addition of the "Osteoporosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Osteoporosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoporosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoporosis. Scope - A snapshot of the global therapeutic scenario for Osteoporosis. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoporosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Affectis Pharmaceuticals AG Amgen Inc. B&C Biopharm Biodel Inc. Bone Medical Limited Calzada Limited Critical Pharmaceuticals Limited DONGKOOK Pharmaceutical Co., Ltd. Dongwha Pharm Co., Ltd. Eli Lilly and Company EndoCeutics, Inc. Ensoltek Co., Ltd. F. Hoffmann-La Roche Ltd. Galapagos NV HYUNDAI PHARM. CO., LTD. Hindustan Latex Limited IMMD Inc. Kaken Pharmaceutical Co.,Ltd. Merck & Co., Inc. NeoStem, Inc. Novartis AG Oscotec Inc. Pfizer Inc. Radius Health, Inc. Siena Biotech S.p.A. TSRL, Inc. Uni-Bio Science Group Ltd. Ventria Bioscience Zelos Therapeutics, Inc. Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/9t...teoporosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Osteoarthritis - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkkfb7/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H2 2013" report to their offering. 'Osteoarthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis. Scope - A snapshot of the global therapeutic scenario for Osteoarthritis. - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoarthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Osiris Therapeutics, Inc. Seikagaku Corporation Sanofi-Aventis Ablynx TiGenix NV Novartis AG Astellas Pharma Inc. Chong Kun Dang Pharmaceutical Chugai Pharmaceutical Co. Ltd Pfizer Inc. Menarini Group Merck KGaA Bone Medical Limited Addex Pharmaceuticals Can-Fite BioPharma Ltd. Medivir AB Mesoblast Ltd Calzada Limited NicOx SA and many more... For more information visit http://www.researchandmarkets.com/research/nk...oarthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bone Disorders - Pipeline Review, H1 2013
M2 - Fri Mar 22, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lqxhlr/bone_disorders) has announced the addition of the "Bone Disorders - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Bone Disorders - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bone Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Disorders. Scope - A snapshot of the global therapeutic scenario for Bone Disorders. - A review of the Bone Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherap
Global Cachexia Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pggqhv/cachexia) has announced the addition of the "Cachexia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cachexia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cachexia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cachexia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cachexia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - GlaxoSmithKline plc - Plexxikon Inc. - BioLineRx, Ltd. - Novartis AG - Aphios Corporation - Calzada Limited - Palatin Technologies, Inc. - Cytokinetics, Incorporated - Fate Therapeutics, Inc. - AVEO Pharmaceuticals, Inc. - Fountain Biopharma Inc. - Rhythm Pharmaceuticals - MI.TO. Technology S.r.L. For more information visit http://www.researchandmarkets.com/research/pggqhv/cachexia
Cartilage Degeneration - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 17, 3:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/hzb6kb/cartilage) has announced the addition of the "Cartilage Degeneration - Pipeline Review, H2 2013" report to their offering. 'Cartilage Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cartilage Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cartilage Degeneration. Scope - A snapshot of the global therapeutic scenario for Cartilage Degeneration. - A review of the Cartilage Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cartilage Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cartilage Degeneration Overview Therapeutics Development Clinical Stage Products Early Stage Products Cartilage Degeneration - Products under Development by Companies Cartilage Degeneration - Companies Involved in Therapeutics Development Cartilage Degeneration - Therapeutics Assessment Drug Profiles sprifermin - Drug Profile Chondrogen - Drug Profile MSB-CAR-001 - Drug Profile AOD-9604 - Drug Profile THR-166 - Drug Profile ST-03 - Drug Profile Cartilage Degeneration - Recent Pipeline Updates Appendix List of Tables List of Figures Companies Mentioned Sanofi Merck KGaA Mesoblast Limited Calzada Limited Thrasos, Inc. For more information visit http://www.researchandmarkets.com/research/hzb6kb/cartilage About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Bone Degeneration Market Report 2013
M2 - Mon Dec 09, 6:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/94cktb/bone_degeneration) has announced the addition of the "Global Bone Degeneration Market Report 2013" report to their offering. This report provides information on the therapeutic development for Bone Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Degeneration. The analysis is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Bone Degeneration. - A review of the Bone Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bone Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bone Degeneration. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bone Degeneration pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: Table of Contents List of Tables List of Figures Introduction REPORT COVERAGE Bone Degeneration Overview Therapeutics Development Companies Involved in Bone Degeneration Therapeutics Development Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Amgen Inc. - Cell Therapeutics, Inc. - Calzada Limited - Alethia Biotherapeutics Inc. - Fate Therapeutics, Inc. - Se-cure Pharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/94...generation
Osteoporosis - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Osteoporosis
M2 - Tue Sep 03, 9:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9tgmch/osteoporosis) has announced the addition of the "Osteoporosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Osteoporosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoporosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoporosis. Scope - A snapshot of the global therapeutic scenario for Osteoporosis. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoporosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Affectis Pharmaceuticals AG Amgen Inc. B&C Biopharm Biodel Inc. Bone Medical Limited Calzada Limited Critical Pharmaceuticals Limited DONGKOOK Pharmaceutical Co., Ltd. Dongwha Pharm Co., Ltd. Eli Lilly and Company EndoCeutics, Inc. Ensoltek Co., Ltd. F. Hoffmann-La Roche Ltd. Galapagos NV HYUNDAI PHARM. CO., LTD. Hindustan Latex Limited IMMD Inc. Kaken Pharmaceutical Co.,Ltd. Merck & Co., Inc. NeoStem, Inc. Novartis AG Oscotec Inc. Pfizer Inc. Radius Health, Inc. Siena Biotech S.p.A. TSRL, Inc. Uni-Bio Science Group Ltd. Ventria Bioscience Zelos Therapeutics, Inc. Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/9t...teoporosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Osteoarthritis - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkkfb7/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H2 2013" report to their offering. 'Osteoarthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis. Scope - A snapshot of the global therapeutic scenario for Osteoarthritis. - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoarthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Osiris Therapeutics, Inc. Seikagaku Corporation Sanofi-Aventis Ablynx TiGenix NV Novartis AG Astellas Pharma Inc. Chong Kun Dang Pharmaceutical Chugai Pharmaceutical Co. Ltd Pfizer Inc. Menarini Group Merck KGaA Bone Medical Limited Addex Pharmaceuticals Can-Fite BioPharma Ltd. Medivir AB Mesoblast Ltd Calzada Limited NicOx SA and many more... For more information visit http://www.researchandmarkets.com/research/nk...oarthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bone Disorders - Pipeline Review, H1 2013
M2 - Fri Mar 22, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lqxhlr/bone_disorders) has announced the addition of the "Bone Disorders - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Bone Disorders - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bone Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Disorders. Scope - A snapshot of the global therapeutic scenario for Bone Disorders. - A review of the Bone Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherap
